Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis

Gao, Song; Zhao, Zhiying; Zhang, Zhen-Yong; Zhang, Yue; Wu, Rong

doi:10.1038/s41424-018-0070-z

Cited by 22 publications

(16 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accumulating evidence has suggested the association between miR-133a and poor overall survival (OS) of patients with solid cancer 67 , 68 . A meta-analysis revealed that high expression of miR-133a was related to better prognosis and ameliorated clinicopathological features in digestive system cancers 69 .…”

Section: Mir-133a In Cancer Prognosismentioning

confidence: 99%

Emerging roles of MiR-133a in human cancers

Hua¹,

Xu²,

Li³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

MicroRNAs (miRNAs) can post-transcriptionally regulate the expression of cancer-relevant genes via binding to the 3'-untranslated region (3'-UTR) of the target mRNAs. MiR-133a, as a miRNA, participate in tumorigenesis, progression, autophagy and drug-resistance in various malignancies. Based on the recent insights, we discuss the functions of miR-133a in physiological and pathological processes and its potential effects on cancer diagnosis, prognosis and therapy.

show abstract

Section: Mir-133a In Cancer Prognosismentioning

confidence: 99%

Emerging roles of MiR-133a in human cancers

Hua¹,

Xu²,

Li³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRNAs), a group of small single-strand non-coding RNAs, can inhibit mRNA translation or induce mRNA degradation by specifically binding to the 3' untranslated region sequence of mRNA target, thus regulating post-transcriptional gene expression[7]. MiRNAs participate in the progression, proliferation, and metastasis of cancer cells in almost all human cancers including ESCC[8]. MiRNAs are expressed in peripheral blood and tissues.…”

Section: Introductionmentioning

confidence: 99%

Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma

Wang¹,

Guo²,

Cui³

et al. 2019

WJG

View full text Add to dashboard Cite

BACKGROUNDEsophageal squamous cell carcinoma (ESCC) is one of the main causes of human death. It is usually already in middle or advanced stage when diagnosed due to its hidden symptoms in early stage. Therefore, patients have already lost the best surgical timing when diagnosed. Radiotherapy and chemotherapy are standard treatment methods for ESCC clinically, but the efficacy and prognosis of patients from them are still unsatisfactory. Therefore, it is of great clinical significance to seek for biomarkers that can predict the radiotherapy and chemotherapy response and prognosis of ESCC patients.AIMTo explore the clinical value of plasma miR-21 and miR-93 in ESCC.METHODSA total of 128 ESCC patients admitted to the First Affiliated Hospital of Zhenzhou University were enrolled as a study group and treated with concurrent radiotherapy and chemotherapy, and other 45 healthy people during the same period were enrolled as a control group. The expression of plasma miR-21 and miR-93 was determined using quantitative real-time polymerase chain reaction, and the correlation of expression of plasma miR-21 and miR-93 with clinical pathological parameters about the patients was analyzed. The receiver operating characteristic (ROC) curve was adopted to assess the diagnostic value of plasma miR-21 and miR-93 for clinical pathological features of ESCC patients, the Logistic regression analysis adopted to analyze the risk factors for radiotherapy and chemotherapy efficacy in ESCC patients, and the Cox regression analysis to identify the prognostic factors for ESCC patients.RESULTSThe study group showed significantly higher relative expression of plasma miR-21 and miR-93 than the control group (P < 0.01). The area under the ROC curve (AUC) of plasma miR-21 for diagnosing T stage, N stage, M stage, and pathological differentiation of ESCC was 0.819, 0.758, 0.824, and 0.725, respectively, and that of plasma miR-93 for diagnosing T stage, N stage, and M stage of ESCC was 0.827, 0.815, and 0.814, respectively. The AUC of combined plasma miR-21 and miR-93 for predicting radiotherapy and chemotherapy efficacy before radiotherapy and chemotherapy was 0.894, and the AUCs of them for predicting the 3-year overall survival (OS) were 0.861 and 0.807, respectively. T stage (P < 0.05), M stage (P < 0.05), miR-21(P < 0.01), and miR-93 (P < 0.05) were independent risk factors for radiotherapy and chemotherapy efficacy, and T stage (P < 0.01), N stage (P < 0.05), M stage (P < 0.01), miR-21 (P < 0.01), and miR-93 (P < 0.01) were independent prognostic factors for ESCC patients.CONCLUSIONMiR-21 and miR-93 can be adopted as effective biomarkers for predicting radiotherapy and chemotherapy efficacy in ESCC and the 3-year OS of ESCC patients.

show abstract

“…Compared with normal samples, 21 significant DEMs were identified. Among them, hsa-miR-147e [ 46 ], hsa-miR-181d [ 47 ], hsa-miR-214 [ 48 , 49 ], hsa-miR-612 [ 50 ], hsa-miR-133b [ 51 ], hsa-miR-143 [ 52 – 55 ], hsa-miR-100 [ 56 ], hsa-miR-126* [ 57 ], hsa-miR-145 [ 52 , 58 – 60 ], hsa-miR-15b [ 61 ] were all reported in EC. Most importantly, hsa-miR-496, hsa-miR-214, hsa-miR-15b were found to be correlated with patient survival.…”

Section: Discussionmentioning

confidence: 99%

Identification of miRNAs and genes for predicting Barrett’s esophagus progressing to esophageal adenocarcinoma using miRNA-mRNA integrated analysis

Yao

Luo

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Barrett’s esophagus (BE) is defined as any metaplastic columnar epithelium in the distal esophagus, which predisposes to esophageal adenocarcinoma (EAC). Yet, the mechanism through which BE develops to EAC still remain unclear. Moreover, the miRNA-mRNA regulatory network in distinguishing BE from EAC still remains poorly understood. To identify differentially expressed miRNAs (DEMs) and genes (DEGs) between EAC and BE from tissue samples, gene expression microarray datasets GSE13898, GSE26886, GSE1420 and miRNA microarray datasets GSE16456, GSE20099 were downloaded from Gene Expression Omnibus (GEO) database. GEO2R was used to screen the DEMs and DEGs. Pathway and functional enrichment analysis were performed by DAVID database. The protein–protein interaction (PPI) network was constructed by STRING and been visualized by Cytoscape software. Finnal, survival analysis was performed basing TCGA database. A total of 21 DEMs were identified. The enriched functions and pathways analysis inclued Epstein-Barr virus infection, herpesvirus infection and TRP channels. GART, TNFSF11, GTSE1, NEK2, ICAM1, PSMD12, CTNNB1, CDH1, PSEN1, IL1B, CTNND1, JAG1, CDH17, ITCH, CALM1 and ITGA6 were considered as the hub-genes. Hsa-miR-143 and hsa-miR-133b were the highest connectivity target gene. JAG1 was predicted as the largest number of target miRNAs. The expression of hsa-miR-181d, hsa-miR-185, hsa-miR-15b, hsa-miR-214 and hsa-miR-496 was significantly different between normal tissue and EAC. CDH1, GART, GTSE1, NEK2 and hsa-miR-496, hsa-miR-214, hsa-miR-15b were found to be correlated with survival.

show abstract

Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis

Cited by 22 publications

References 97 publications

Emerging roles of MiR-133a in human cancers

Emerging roles of MiR-133a in human cancers

Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma

Identification of miRNAs and genes for predicting Barrett’s esophagus progressing to esophageal adenocarcinoma using miRNA-mRNA integrated analysis

Contact Info

Product

Resources

About